Ludwig Cancer Research is pleased to welcome Nancy E. Davidson to the Ludwig Institute Board of Directors. Nancy Davidson, a physician-scientist with extensive expertise in breast cancer research, is a leader in the cancer research community.
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells–which kill infected and cancerous cells–and demonstrates how they can be identified and selectively grown for u…
Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.
Ludwig Cancer Research has released the scope of its participation at this year’s Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, November 16-19.
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy.